Specialty drugs are the majority of 340B dollars. Most of them are infused.
Oncology and infusion service lines sit at the intersection of the largest 340B spending category and the most contested reimbursement environment in outpatient care. The two cannot be advised on separately.
At a glance
- 01Specialty share of 340B $
- ~62%
- 02Cancer share of infusion
- ~31%
- 03Site-neutral pressure
- Ongoing
- 04Modeled together
- 340B + reimbursement
Four pressures, arriving simultaneously
Site-neutral payment policy compresses reimbursement on the most common infusion codes when delivered in a hospital outpatient department, accelerating migration toward freestanding sites — which may not carry the same 340B eligibility.
White bagging moves drug acquisition to a payer-designated specialty pharmacy. The drug never appears on your books, which removes both the margin and the 340B volume while leaving you with the handling and safety obligation.
Manufacturer restrictions concentrate hardest on high-cost specialty products, which is exactly the drug mix an oncology service line depends on.
Payer steerage directs patients toward provider-preferred sites of care, which changes volume assumptions in any model built before it started.
Each of these is often handled by a different function inside a health system. That is the structural reason they are rarely modeled together — and the reason the model is usually wrong.
One model, three disciplines
We build the model that holds operations, reimbursement and 340B eligibility simultaneously — because in this service line, changing one always moves the other two.
- Chair utilization, throughput and scheduling analysis
- Payer mix and reimbursement modeling by code and site of service
- 340B eligibility impact of any proposed site-of-care change
- White bagging exposure by payer and by drug, with response strategy
- Referral pattern and leakage analysis across the service line
- Manufacturer restriction impact on your specific specialty drug mix
Oncology and infusion — common questions
01Is our hospital-based infusion center 340B eligible?
It depends on whether the location is a registered site, its relationship to the covered entity, and whether it appears correctly on the Medicare cost report. Many organizations assume eligibility for a location that was never formally registered, or that was registered but is mapped incorrectly in the split billing system.
02What can we do about white bagging?
Options include payer contract negotiation, clinical handling and safety policy, patient access argument, and in some states legislative protection. The right combination depends on your payer concentration and your state. We assess exposure by payer and drug, then help build the response that matches your actual leverage.
03Should we move infusion to a freestanding site?
Sometimes — but not before modeling the 340B eligibility consequence alongside the facility cost saving. On a service line where drug cost dominates, the eligibility variable frequently outweighs the operational savings that motivated the question. We have seen this reverse a decision more than once.
04Do you work with community oncology practices?
We work with hospital-based and health-system oncology service lines on the 340B side. Independent community practices are generally not 340B covered entities, though we do advise on infusion operations and reimbursement where 340B is not part of the picture.
Marked up with FAQPage schema for search and AI-answer eligibility.
Next step
Bring us the pro forma you already have.
The fastest value we usually add is telling you which variable it left out.